In This Issue
The Role of IORT in Breast Cancer Treatment
New Study on Strut-Based Breast Brachytherapy
APBI Updates
BrachyBytes Editorial Advisory Board

Robert Kuske, M.D.

Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
Upcoming Events


American Association of Physicists in Medicine Annual Meeting 

August 4-8, 2013

Indiana Convention Center
Indianapolis, IN

Breast Cancer Symposium
September 7-9, 2013

Marriott Marquis Hotel
San Francisco, CA


American Society of Radiation Oncology Annual Meeting

September 22-25,
20213 Georgia World Congress Center Atlanta, GA


Become a Center of Excellence in APBI

Learn about becoming a
Center of Excellence and find ways to grow your
APBI program by reaching out to referring physicians and women in the community.

Contact for more information.  
Follow-up Links

Past Issues
Cianna Medical

BEST Forum
SAVI Sisters

VCU Massey Cancer Center American Brachytherapy Society

May 2013 

The Role of IORT in Breast Cancer Treatment 
Douglas Arthur, MD Douglas Arthur, MD

Intraoperative radiation therapy (IORT) is a method of partial breast irradiation treatment delivery being studied in phase III trials that reduces treatment from five days of postoperative delivery to one intraoperative treatment. The potential advantages of IORT are clear, particularly the increased convenience for patients.

However, many physicians feel a number of issues need to be addressed before widespread adoption will occur. Radiation oncologist Douglas Arthur, MD, outlines current IORT techniques and shares his views on the emerging modality, including the need for more data before IORT can be adopted as a standard of care. Read More

BONUS: Read Dr. Arthur’s presentation on IORT from the recent American Brachytherapy Society meeting. Download now

New Study: Strut-based Brachytherapy is Effective for Early-Stage Breast Cancer

Strut-based breast brachytherapy has been shown to to be a well-tolerated, effective treatment, according to a multi-institutional study of 320 patients with a median follow up of three years.

The research was presented at the annual meeting of the American Society of Breast Surgeons, held in Chicago, May 1-5, 2013.

Read more

SAVI Breast Brachytherapy: Favorable Toxicity at 4 Years

APBI Updates

Updated ABS Consensus StatementAmerican Brachytherapy Society

As more research has been published showing the efficacy of APBI, the American Brachytherapy Society recently released updated guidelines to provide physicians with appropriate patient selection criteria. Among the most significant changes:

  • Histology: All invasive subtypes and ductal carcinoma in situ (DCIS) are now acceptable.
  • Receptor status: Estrogen receptor may be positive or negative.
  • LVSI: The presence of lymphovascular invasion (LVSI) is a contraindication for APBI.

Read ABS consensus statement on APBI

NSABP B-39 Closure

NSABP B-39/RTOG 0413 closed to patient accrual on April 17, 2013. NSABP B-39 is a randomized Phase III trial comparing the efficacy of APBI to conventional whole breast irradiation. Recurrence rates are not expected to be published until there are enough events to report.